SRC and pulmonary fibrosis: However, because nintedanib, which is a multi-targeted tyrosine kinase inhibitor, also has inhibitory effects on tyrosine kinases involved in inflammation other than Lck, such as Src [18, 37], the present study is the first report to examine the effect of Lck-specific inhibition on lung fibrosis.